Table 1 Examples of bioengineered MSCs with therapeutic proteins.
From: Engineered mesenchymal stem/stromal cells against cancer
Engineered Agent | MSC source | Tumor Model | Mechanism | Refs |
|---|---|---|---|---|
IFN-α | Mouse BM-MSCs | The mouse melanoma cell line B16F10 | Induction of tumor cells and endothelial cell apoptosis | [49] |
Mouse BM-MSCs | The mouse melanoma cell line B16F0 and colon carcinoma tumor cell line MC38 | Potentiate the cytotoxicity of CD8+.T cells and promote CD8+ T cell infiltration into tumor tissues | [50] | |
IFN-β | Human BM-MSCs | The mouse melanoma cell line A375SM | Inhibit the growth of malignant cells | [51] |
Mouse BM-MSCs | The mouse metastatic prostate cancer cell line TRAMP-C2 | Increase the natural kill cell activity | [54] | |
Mouse MSCs (The source was not mentioned) | The mouse breast cancer cell line 4T1 | Inhibit STAT3 signaling; reduce pulmonary and hepatic metastases | [55] | |
Mouse MSCs (The source was not mentioned) | The mouse glioblastoma multiforme cell line CT-2A and GL261 | Enhance selective post-surgical infiltration of CD8+ T cells; induce cell-cycle arrest in tumor cells | [137] | |
IFN-γ | Human BM-MSCs | The human neuroblastoma cell lines CHLA-255 and CHLA-20 | Promote proinflammatory polarization of macrophages | [38] |
IL-2 | Rat BM-MSCs | The rat glioma cell line 9 L | Inhibit tumor growth | [61] |
Mouse BM- MSCs | The mouse melanoma cell line B16F0 | Develop CD8+ T cell-mediated tumor-specific immunity and delay tumor growth | [62] | |
Mouse BM-MSCs | The mouse melanoma cell line B16F0, colon carcinoma MC38 and CT26 and breast cancer cell line 4T1 | Rejuvenate exhausted TILs by expanding PD1+TIM3−CD8+ T cells and reinvigorating cytotoxic activities | [125] | |
IL-12 | Human UB-MSCs | The human glioma cell line GL261 | Enhance IFN-γ secretion and T cell infiltration as well as anti-angiogenesis | [64] |
Mouse BM-MSCs | Primary and metastatic B16F10 melanomas | Decrease vascular density and increase the number of anticancer proinflammatory macrophages and CD8+ cytotoxic T lymphocytes in tumors | [65] | |
IL-18 | Human UC-MSCs | The human breast cancer cell line MCF-7 and HCC1937 | Inhibit tumor cell growth, migration and invasion in vitro | [67] |
IL-21 | Human UB-MSCs | The human primary ovarian cancer cell | Increase IFNγ-secreting splenocyte numbers and natural killer cytotoxicities | [68] |
Human UC-MSCs | The human ovarian cancer cell line SKOV-3 | Increase the expression of NKG2D and MIC-A molecules in the tumor tissues, and inhibit SKOV3 ovarian cancer growth by downregulate β-catenin and cyclin-D1 in the tumor tissues | [69] | |
Trail | Human UB- MSCs | The human glioma cell line U-87MG, U-251MG and A172 | Not elucidated | [70] |
Human AD-MSCs | The human lung cancer cell line H460 | Increase tumor apoptosis | [71] | |
IL-12+Trail | Mouse BM-MSCs | The mouse lymphoma cell line L5178Y | Increase tumor apoptosis | [138] |
